β¨ Medicines Distribution Consents
NEW ZEALAND GAZETTE
No. 102
2796
Product:
Risperdal Consta
Active Ingredient:
Risperidone 25mg
Dosage Form:
Vial Powder for injection
New Zealand Sponsor:
Janssen-Cilag Pty Limited
Manufacturer:
Alkermes, Wilmington, Ohio, United States of America
Product:
Risperdal Consta
Active Ingredient:
Risperidone 37.5mg
Dosage Form:
Vial Suspension for injection
New Zealand Sponsor:
Janssen-Cilag Pty Limited
Manufacturer:
Alkermes, Wilmington, Ohio, United States of America
Product:
Risperdal Consta
Active Ingredient:
Risperidone 50mg
Dosage Form:
Vial Suspension for injection
New Zealand Sponsor:
Janssen-Cilag Pty Limited
Manufacturer:
Alkermes, Wilmington, Ohio, United States of America
Dated this 7th day of August 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go5410
Renewal of Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product:
Zopine
Active Ingredient:
Clozapine 100mg
Dosage Form:
Tablet
New Zealand Sponsor:
Pacific Pharmaceuticals Limited
Manufacturer:
Alphapharm Pty Limited, Carole Park, Brisbane, Queensland, Australia
This consent is given subject to the following conditions:
- The medicine may only be prescribed by:
- medical practitioners who are vocationally registered under the Medical Practitioners Act 1995 in the branches of psychological medicine or psychiatry; and
- medical practitioners employed as registrars in psychological medicine or psychiatry who are under the supervision of persons of the kind referred to above.\n- Persons prescribing the medicine must comply with the requirements of the New Zealand Guidelines for the use of Atypical Anti-Psychotic Drugs (2nd Edition September 1998) and the requirements of local hospital and health service protocols for the use of clozapine.
Note: This consent is valid for two years from 19 October 2002.
Product:
Zopine
Active Ingredient:
Clozapine 25mg
Dosage Form:
Tablet
New Zealand Sponsor:
Pacific Pharmaceuticals Limited
Manufacturer:
Alphapharm Pty Limited, Carole Park, Brisbane, Queensland, Australia
This consent is given subject to the following conditions:
- The medicine may only be prescribed by:
- medical practitioners who are vocationally registered under the Medical Practitioners Act 1995 in the branches of psychological medicine or psychiatry; and
- medical practitioners employed as registrars in psychological medicine or psychiatry who are under the supervision of persons of the kind referred to above.\n- Persons prescribing the medicine must comply with the requirements of the New Zealand Guidelines for the use of Atypical Anti-Psychotic Drugs (2nd Edition September 1998) and the requirements of local hospital and health service protocols for the use of clozapine.
Note: This consent is valid for two years from 19 October 2002.
Dated this 7th day of August 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go5411
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2002, No 102
Gazette.govt.nz —
NZ Gazette 2002, No 102
β¨ LLM interpretation of page content
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare7 August 2002
Medicines, Approval, Distribution, Risperdal Consta, Janssen-Cilag, Alkermes
- G. R. Boyd, Chief Advisor, Safety and Regulation
π₯ Renewal of Provisional Consent to the Distribution of a New Medicine
π₯ Health & Social Welfare7 August 2002
Medicines, Provisional Consent, Renewal, Zopine, Clozapine, Pacific Pharmaceuticals, Alphapharm
- G. R. Boyd, Chief Advisor, Safety and Regulation